AR102903A1 - DRY POWDER INHALER - Google Patents
DRY POWDER INHALERInfo
- Publication number
- AR102903A1 AR102903A1 ARP140103722A ARP140103722A AR102903A1 AR 102903 A1 AR102903 A1 AR 102903A1 AR P140103722 A ARP140103722 A AR P140103722A AR P140103722 A ARP140103722 A AR P140103722A AR 102903 A1 AR102903 A1 AR 102903A1
- Authority
- AR
- Argentina
- Prior art keywords
- dry powder
- dose
- patient
- salmeterol
- powder inhaler
- Prior art date
Links
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 abstract 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 229960000289 fluticasone propionate Drugs 0.000 abstract 2
- WMWTYOKRWGGJOA-CENSZEJFSA-N fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 abstract 2
- 239000008101 lactose Substances 0.000 abstract 2
- 239000000843 powder Substances 0.000 abstract 2
- 230000010349 pulsation Effects 0.000 abstract 2
- 229960004017 salmeterol Drugs 0.000 abstract 2
- 229960005018 salmeterol xinafoate Drugs 0.000 abstract 2
- 229940112141 dry powder inhaler Drugs 0.000 abstract 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Un inhalador de polvo seco que comprende: un medicamento de polvo seco que comprende propionato de fluticasona, xinafoato de salmeterol y un portador de lactosa; en el que, la dosis administración de salmeterol por pulsación es menor de 50 mg; y en el que la dosis proporciona un FEV₁ ajustado a valores basales en un paciente de no más de 150 ml dentro de los 30 minutos de recibir la dosis. Un método de tratar un paciente incluye administrar a un paciente un medicamento de polvo seco que tiene propionato de fluticasona, xinafoato de salmeterol y un portador de lactosa; en el que, la dosis administración de salmeterol por pulsación es menor de 50 mg; y en el que la dosis proporciona un FEV₁ ajustado a valores basales en un paciente de más de 150 ml dentro de los 30 minutos de recibir la dosis.A dry powder inhaler comprising: a dry powder medicament comprising fluticasone propionate, salmeterol xinafoate and a lactose carrier; wherein, the dose administration of salmeterol by pulsation is less than 50 mg; and in which the dose provides a FEV₁ adjusted to baseline values in a patient of no more than 150 ml within 30 minutes of receiving the dose. One method of treating a patient includes administering to a patient a dry powder medicine having fluticasone propionate, salmeterol xinafoate and a lactose carrier; wherein, the dose administration of salmeterol by pulsation is less than 50 mg; and in which the dose provides a FEV₁ adjusted to baseline values in a patient of more than 150 ml within 30 minutes of receiving the dose.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361887589P | 2013-10-07 | 2013-10-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR102903A1 true AR102903A1 (en) | 2017-04-05 |
Family
ID=58672832
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP140103722A AR102903A1 (en) | 2013-10-07 | 2014-10-06 | DRY POWDER INHALER |
Country Status (1)
| Country | Link |
|---|---|
| AR (1) | AR102903A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117771490A (en) * | 2023-12-20 | 2024-03-29 | 上海新黄河制药有限公司 | A kind of double reservoir powder aerosol device |
-
2014
- 2014-10-06 AR ARP140103722A patent/AR102903A1/en unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117771490A (en) * | 2023-12-20 | 2024-03-29 | 上海新黄河制药有限公司 | A kind of double reservoir powder aerosol device |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2016004316A (en) | Dry powder inhaler. | |
| AR104771A1 (en) | DRY POWDER INHALER | |
| AR095338A1 (en) | NON-TOXIC TREATMENT METHOD FOR DRUG ABSTINENCE | |
| AR097178A1 (en) | DIAGNOSIS AND ANTI-CANCER THERAPIES THAT INCLUDE CANCEROSE MOTHER CELLS | |
| MX2015013355A (en) | THERAPY INVOLVING ANTIBODIES AGAINST CLAUDINE 18.2 FOR THE CANCER TREATMENT. | |
| PE20142319A1 (en) | MULTIPLE SCLEROSIS TREATMENT WITH A COMBINATION OF LAQUINIMOD AND GLATIRAMER ACETATE | |
| PE20150161A1 (en) | USE OF HIGH DOSE LAQUINIMOD FOR THE TREATMENT OF MULTIPLE SCLEROSIS | |
| MX2022009231A (en) | DRY POWDER INHALER AND METHOD OF USE. | |
| BR112017006272A2 (en) | The medicine constituent for medical treatment of chronic ulcerative colitis | |
| CO2021016606A2 (en) | Methods of administering an anti-cd38 antibody to treat multiple myeloma | |
| HK1245153A1 (en) | Btk inhibitor combinations and dosing regimen | |
| AR088204A1 (en) | MEDICINES FOR THE TREATMENT OF ALLERGY RHINITIS THAT INCLUDE A PGD2 ANTAGONIST AND A HISTAMINE ANTAGONIST | |
| MX2015009546A (en) | Increased dosage of efavirenz for the treatment of cancer. | |
| BR102012028120B8 (en) | USE OF ONE OR MORE INGENOL DERIVATIVES, PHARMACEUTICAL COMPOSITION AND DRUG | |
| UY35890A (en) | USE OF LAQUINIMOD TO DELAY THE PROGRESSION OF HUNTINGTON'S DISEASE | |
| MX2015016418A (en) | Dihydroetorphine for the provision of pain relief and anaesthesia. | |
| AR102903A1 (en) | DRY POWDER INHALER | |
| AR094287A1 (en) | METHODS AND COMPOSITIONS FOR OXIBUTININE ADMINISTRATION | |
| RU2011101481A (en) | METHOD FOR PREVENTION OF ACUTE DECOMPRESSION DISEASE | |
| UA105586U (en) | Method for treating hepatic encephalopathy | |
| TH173838A (en) | Dry powder nebulizer | |
| AR114012A1 (en) | METHOD OF PROVIDING CELIPROLOL THERAPY TO A PATIENT | |
| UA71921U (en) | Method for treating toxic neuroretinopathy of alcohol etiology | |
| AR098924A1 (en) | TREATMENT OF MULTIPLE SCLEROSIS WITH A COMBINATION OF LAQUINIMOD AND TERIFLUNOMIDE | |
| BR112019005168A2 (en) | pharmaceutical composition, sealed container, metered dose inhaler, and methods for treating a patient suffering or likely to suffer from a respiratory disorder, for improving the stability of a pharmaceutical composition and the aerosolization performance of a pharmaceutical composition global warming potential of a pharmaceutical composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |